Skip to NavigationSkip to content

News

Eli Lilly has released new Phase 3 results for its CGRP inhibitor galcanezumab in the treatment of episodic cluster headache, showing that the...
The saga of Novartis’ ill-advised $1.2 million deal with US President Donald Trump’s lawyer Michael Cohen continues to unfold as it emerges that...
Pfizer’s Retacrit, a biosimilar version of Amgen’s Epogen and Janssen’s Procrit, has been approved for use in the US by the FDA, making it the...
Researchers from Imperial College London have discovered how to interfere with one of the building blocks that allows the common cold to replicate...
We are in the midst of a breath-taking series of changes in the world of pharmacovigilance, both within Europe and beyond and this has prompted new...
Researchers from the University of Texas MD Anderson Cancer Center have been developing and testing a new model for the better design and...
The FDA has noted a number of failings at a plant in Gujarat, India, but mostly significantly was the finding that the company had failed to test for...
Asymptomatic carriers of malaria may be responsible for the onwards transmission of up to 90% of cases, new research has been able to identify these...
UK-based biotech, Emergex Vaccines, has received £1 million to push its universal flu vaccine through preclinical tests, in the hope of progressing...
Eli Lilly has agreed to acquire AurKa Pharma in an agreement with a total potential value of $575 million, representing yet another step in the...
Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches